Explain this page
Arphra AIPlain-English read on AbbVie Inc.’s valuation06-03today
- AbbVie (ABBV) Rises Higher Than Market: Key Facts16h
- AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.1d
- AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results1d
- AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results1d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
$1,652.36
+625.58% vs spot
Recommendation
Strong Buy
15 of 17 methods
Method spread
4bull10bear
±5% threshold
Analyst PT consensus: $257.54 (+13.09%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.32% | +0.43% | +9.22% | +3.66% | +1.97% | -0.33% | +19.18% | +64.65% | +97.34% | +279.99% | +550.66% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$34.15M
10 txns
Net flow
−$34.15M
Aftermarket
LiveLast trade
$227.25
Bid
$224.00
1 sh
Ask
$229.60
10 sh
Spread
$5.600
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Mar 2026 | $15B | $699M | $0.39 |
| Q4 Dec 2025 | $16.62B | $1.82B | $1.02 |
| Q3 Sep 2025 | $15.78B | $186M | $0.10 |
| Q2 Jun 2025 | $15.42B | $938M | $0.53 |
| Q1 Mar 2025 | $13.34B | $1.29B | $0.72 |
| Q4 Dec 2024 | $15.1B | -$22M | $-0.02 |
Analyst view
DB · price_targets + analyst_gradesConsensus target
$257.54
+13.09% upside
Low
$223.00
Median
$260.00
High
$298.00
Recent actions
0 ↑0 ↓8 hold
- May 01, 2026
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
News
DB · news_items- AbbVie (ABBV) Rises Higher Than Market: Key Factszacks.com·Jun 12, 2026
- AbbVie Reports Promising New Clinical Updates. Here's What It Means for the Company's Dividend.fool.com·Jun 12, 2026
- AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Resultsprnewswire.com·Jun 12, 2026
- AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Resultsprnewswire.com·Jun 12, 2026
- AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Resultsprnewswire.com·Jun 12, 2026
- AbbVie: Growth-Pharma Profile At A Value-Pharma Priceseekingalpha.com·Jun 11, 2026
- Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225247wallst.com·Jun 11, 2026
- Will Skyrizi & Rinvoq Continue to Drive AbbVie's Topline Through 2026?zacks.com·Jun 11, 2026
Peers
Total assets
$133.96B
Total debt
$69.07B
Cash & equiv
$5.23B
Operating CF
$19.03B
Free cash flow
$17.82B
Buybacks
-$980M
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Purdue David Ryan officer: SVP, Controller | Sell | 5,230 | $1.22M | Mar 04, 2026 |
Siatis Perry C officer: EVP, GC AND SECRETARY | Sell | 5,777 | $1.35M | Mar 02, 2026 |
Siatis Perry C officer: EVP, GC AND SECRETARY | Sell | 2,600 | $611.68K | Mar 02, 2026 |
Siatis Perry C officer: EVP, GC AND SECRETARY | Sell | 10,291 | $2.41M | Mar 02, 2026 |
Siatis Perry C officer: EVP, GC AND SECRETARY | Sell | 22,381 | $5.15M | Feb 25, 2026 |
SALEKI-GERHARDT AZITA officer: EVP, CHIEF OPERATIONS OFFICER | Sell | 42,370 | $8.41M | Aug 12, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $61.16B | $20.09B | $4.23B | $2.37 | +6.91% |
| FY 2024 | $56.33B | $9.14B | $4.28B | $2.39 | +7.59% |
| FY 2023 | $54.32B | $12.76B | $4.86B | $2.72 | +8.95% |
| FY 2022 | $58.05B | $18.12B | $11.84B | $6.63 | +20.39% |
| FY 2021 | $56.2B | $17.92B | $11.54B | $6.45 | +20.54% |